A Phase 3 interventional study of Ezetimibe and Simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 47th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 44th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 55th largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 56th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with hypercholesterolemia who satisfy the following criteria:
Exclusion Criteria:
Patients for whom any of the following is applicable:
Patients with hyperlipidemia associated with the following diseases:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ezetimibe 10 mg + Simvastatin 20 mg
Drug: Ezetimibe · Drug: Simvastatin
Ezetimibe 10 mg once daily
Also known as: SCH 58235
Simvastatin 20 mg daily
Number of Participants With Adverse Events and Adverse Reactions
An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was treatment-related was considered an adverse reaction.
Time frame: Throughout 1 year of study
| Milestone | Ezetimibe + Simvastatin |
|---|---|
| Started | 151 |
| Completed | 132 |
| Not completed | 19 |
| Withdrew: Drop in low density lipoprotein (1) | 2 |
| Withdrew: Elevated creatine phosphokinase (2) | 1 |
| Withdrew: Adverse event | 7 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Elevated alanine aminotransferase (3) | 2 |
| Withdrew: Adverse reaction did not improve (4) | 1 |
An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was treatment-related was considered an adverse reaction.
| Participants | Ezetimibe + Simvastatin |
|---|---|
| Adverse Events | 143 |
| Adverse Reactions | 36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe+Simvastatin | — | 17/151 (11.3%) | 127/151 (84.1%) |
| Event | Ezetimibe+Simvastatin |
|---|---|
| CORONARY ARTERY RESTENOSISInjury, poisoning and procedural complications | 3/151 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/151 |
| ANGINA UNSTABLECardiac disorders | 1/151 |
| HYPERTROPHIC CARDIOMYOPATHYCardiac disorders | 1/151 |
| EYE PAINEye disorders | 1/151 |
| PNEUMONIAInfections and infestations | 1/151 |
| IN-STENT CORONARY ARTERY RESTENOSISInjury, poisoning and procedural complications | 1/151 |
| DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders | 1/151 |
| ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders | 1/151 |
| BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/151 |
| Event | Ezetimibe+Simvastatin |
|---|---|
| NASOPHARYNGITISInfections and infestations | 46/151 |
| C-REACTIVE PROTEIN INCREASEDInvestigations | 41/151 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 27/151 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 26/151 |
| MYOGLOBIN BLOOD INCREASEDInvestigations | 21/151 |
| BRONCHITISInfections and infestations | 20/151 |
| BACK PAINMusculoskeletal and connective tissue disorders | 17/151 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 15/151 |
| GAMMA-GLUTAMYLTRANSFERASE INCREASEDInvestigations | 14/151 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 14/151 |
| Age, Customized(Participants) | Ezetimibe + Simvastatin |
|---|---|
| Number | 151 |
| Sex: Female, Male(Participants) | Ezetimibe + Simvastatin |
|---|---|
| Female | 82 |
| Male | 69 |
| Region of Enrollment(participants) | Ezetimibe + Simvastatin |
|---|---|
| Japan | 151 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2007 to primary completion in Jun 2009, 18 months.
Results were first posted in Jun 2010, 1 year after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin